Avid Radiopharmaceuticals: Eli Lilly announces positive results from phase 3 study of PET imaging agent, flortaucipir F 18
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc, a wholly owned subsidiary of Lilly, announced that a phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two
Read full article »
CEO
Avid Radiopharmaceuticals, Inc., is a Private company. Avid Radiopharmaceuticals, Inc.,'s parent company has been Lilly Eli & Co since Dec 2011.